Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

Blood

Volumn 117, Issue 23, 2011, Pages 6375-6382

  Socié, Gérard ^a   Schmoor, Claudia ^b   Bethge, Wolfgang A ^c   Ottinger, Hellmut D ^d   Stelljes, Matthias ^e   Zander, Axel R ^f   Volin, Liisa ^g   Ruutu, Tapani ^g   Heim, Dominik A ^h   Schwerdtfeger, Rainer ⁱ   Kolbe, Karin ^j   Mayer, Jiri ^k   Maertens, Johan A ^l   Linkesch, Werner ^m   Holler, Ernst ⁿ   Koza, Vladimir ^o   Bornhäuser, Martin ^p   Einsele, Hermann ^q   Kolb, Hans Jochem ^r   Bertz, Hartmut ^b   Egger, Matthias ^b   Grishina, Olga ^b   Finke, Jürgen ^b   more..

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY HOSPITAL GRAZ   (Austria)

ⁿ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^o CHARLES UNIVERSITY   (Czech Republic)

^p UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE GLOBULIN ANTIBODY; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA RELAPSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; ORGAN DONOR; OSTEOMYELOFIBROSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; RELAPSE; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

EID: 79959456118     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329821     Document Type: Article

References (45)

1. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1): 14-21.
2. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784-3792. (Pubitemid 350159650)
3. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011-1016.
4. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233. (Pubitemid 40045609)
5. Bhushan V, Collins RH Jr. Chronic graft-vs-host disease. JAMA. 2003;290(19):2599-2603. (Pubitemid 37443290)
6. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97(5):1196-1201. (Pubitemid 32183739)
7. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-1624.
8. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21(8):1480-1484. (Pubitemid 46594099)
9. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102(2):756-762. (Pubitemid 36842003)
10. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101(9):3373-3385. (Pubitemid 36857917)
11. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12):2459-2464. (Pubitemid 20202328)
12. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119- 4126. (Pubitemid 46743372)
13. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102(5):1601-1605. (Pubitemid 37022548)
14. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108-3114. (Pubitemid 46482114)
15. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192-3204.
16. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2(8552):175-178. (Pubitemid 17091848)
17. Blaise D, Gravis G, Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet. 1993;341(8836):51-52. (Pubitemid 23007628)
18. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733-741. (Pubitemid 41207235)
19. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10): 2942-2947.
20. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106(9):3308-3313. (Pubitemid 41565934)
21. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant- related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565. (Pubitemid 43956361)
22. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-1394. (Pubitemid 46965279)
23. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003;21(3):506-513. (Pubitemid 46606481)
24. Schleuning M, Gunther W, Tischer J, Ledderose G, Kolb HJ. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant. 2003;32(3):243-250. (Pubitemid 36927074)
25. Zander AR, Kroger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant- related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant. 2003; 32(4):355-361. (Pubitemid 37038844)
26. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217. (Pubitemid 10036817)
28. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
29. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
30. Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis. 1982;35(6):437-443. (Pubitemid 12117326)
31. Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed. 2004;74(1):69-75. (Pubitemid 38283682)
32. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc. 1989; 84:1074-1078.
33. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York, NY: Springer-Verlag; 1993.
34. Allignol A, Schumacher M, Beyersmann J. Empirical transition matrix of multistate models: the ETM package. J Stat Software. 2011;7(13):1-15.
35. Mohty M, Labopin M, Balére ML, et al. Antithymocyte globulins and chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societé Française de Greffe de Moelle et de Therapie Cellulaire. Leukemia. 2010;24(11):1867-1874.
36. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414. (Pubitemid 34761100)
37. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506. (Pubitemid 39564419)
38. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250-259.
39. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006; 24(36):5695-5702. (Pubitemid 46631311)
40. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12(4):375-396. (Pubitemid 43380955)
41. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 suppl):S146-S151.
42. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant. 2005; 11(10):814-815. (Pubitemid 41403763)
43. Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB. Chronic graft-versus-host disease: implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant. 2008;14(4): 379-384. (Pubitemid 351372747)
44. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12(5):491-505. (Pubitemid 43956368)
45. Soiffer R, LeRademacher J, Ho VT, et al. Impact of in vivo T-cell depletion on outcome of reduced intensity conditioning hematopoietic cell transplantation for hematologic malignancies [Abstract]. Blood. 2010;116(21):951.